Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
phase 3
Pharma
China IIT, Daiichi Sankyo-AZ, Leo-Tanabe—Fierce Pharma Asia
China's alternative trial pathway draws scrutiny. AZ and Daiichi Sankyo's phase 3 lung cancer win. Tanabe's licensing deal. And more.
Donavyn Coffey
Aug 21, 2026 9:00am
Trial results set up Keenova to gain 3rd indication for Xiaflex
Jul 8, 2026 11:27am
Argenx's Vyvgart posts ph. 3 win in ocular myasthenia gravis
Feb 26, 2026 11:18am
Fierce Biotech
US vaccine landscape ‘100%’ impacting business: Bancel
Jan 23, 2026 1:26pm
IntraBio's Aqneursa tees up 2nd rare disease nod with ph. 3 win
Jan 21, 2026 11:48am
Foresee eyes rare puberty disease nod for Camcevi with trial win
Jan 2, 2026 11:03am
Fierce Biotech
Fierce Biotech
Fierce Biotech
Fierce Biotech
